

Disclaimer: This document is an English translation of the original document in Japanese and has been prepared solely for reference purposes. In the event of any discrepancy between this English translation and the original in Japanese, the original shall prevail in all respects.

Consolidated Financial Results for the Nine Months Ended December 31, 2024 [Japanese GAAP]



February 3, 2025

Company name: KISSEI PHARMACEUTICAL CO., LTD.
 Stock exchange listing: Tokyo Stock Exchange
 Stock code: 4547
 URL: <https://www.kissei.co.jp/>
 Representative: Mutsuo Kanzawa, Chairman & CEO
 Contact: Takahide Kitahara, Managing Director, Department Manager of Corporate Finance and Management Department, CFO
 Phone: +81-263-25-9081
 Scheduled date of commencing dividend payments: –
 Availability of supplementary explanatory materials on financial results: Available
 Schedule of financial results briefing session: Not scheduled

(Amounts of less than one million yen are rounded down.)

1. Consolidated Financial Results for the Nine Months Ended December 31, 2024 (April 1, 2024 – December 31, 2024)

(1) Consolidated Operating Results (% indicates changes from the previous corresponding period.)

| | Net sales | | Operating profit | | Ordinary profit | | Profit attributable to owners of parent | |
|-------------------------------------|-------------|------|------------------|-------|-----------------|--------|---|------|
| | Million yen | % | Million yen | % | Million yen | % | Million yen | % |
| Nine months ended December 31, 2024 | 65,669 | 13.5 | 4,238 | 1.8 | 5,298 | (13.1) | 8,840 | 6.0 |
| December 31, 2023 | 57,859 | 12.1 | 4,164 | 745.9 | 6,100 | 188.6 | 8,337 | 25.0 |

(Note) Comprehensive income: Nine months ended December 31, 2024: ¥(723) million [-%]

Nine months ended December 31, 2023: ¥11,697 million [-%]

| | Basic earnings per share | Diluted earnings per share |
|-------------------|--------------------------|----------------------------|
| Nine months ended | Yen | Yen |
| December 31, 2024 | 201.40 | — |
| December 31, 2023 | 182.87 | — |

(2) Consolidated Financial Position

| | Total assets | Net assets | Equity ratio | Net assets per share |
|-------------------|--------------|-------------|--------------|----------------------|
| As of | Million yen | Million yen | % | Yen |
| December 31, 2024 | 248,930 | 211,318 | 84.4 | 4,910.69 |
| March 31, 2024 | 260,929 | 221,136 | 84.3 | 4,977.41 |

(Reference) Equity: As of December 31, 2024: ¥210,202 million

As of March 31, 2024: ¥220,028 million

2. Dividends

| | Annual dividends | | | | |
|--|------------------|-----------------|-----------------|----------|-------|
| | 1st quarter-end | 2nd quarter-end | 3rd quarter-end | Year-end | Total |
| | Yen | Yen | Yen | Yen | Yen |
| Fiscal year ended March 31, 2024 | – | 41.00 | – | 41.00 | 82.00 |
| Fiscal year ending March 31, 2025 | – | 45.00 | – | | |
| Fiscal year ending March 31, 2025 (Forecast) | | | | 45.00 | 90.00 |

(Note) Revision to the forecast for dividends announced most recently: None

3. Consolidated Financial Results Forecast for the Fiscal Year Ending March 31, 2025 (April 1, 2024 – March 31, 2025)

(% indicates changes from the previous corresponding period.)

| | Net sales | | Operating profit | | Ordinary profit | | Profit attributable to owners of parent | | Basic earnings per share |
|-----------|-------------|------|------------------|------|-----------------|-------|---|-----|--------------------------|
| | Million yen | % | Million yen | % | Million yen | % | Million yen | % | Yen |
| Full year | 86,500 | 14.4 | 5,000 | 24.5 | 6,000 | (2.3) | 11,700 | 4.8 | 268.21 |

(Note) Revision to the financial results forecast announced most recently: None

*** Notes:**

- (1) Significant changes in scope of consolidation during the period under review: None
- (2) Accounting methods adopted particularly for the preparation of quarterly consolidated financial statements: None
- (3) Changes in accounting policies, changes in accounting estimates and retrospective restatement
- 1) Changes in accounting policies due to the revision of accounting standards: None
 - 2) Changes in accounting policies other than 1) above: None
 - 3) Changes in accounting estimates: None
 - 4) Retrospective restatement: None
- (4) Total number of issued shares (common shares)
- 1) Total number of issued shares at the end of the period (including treasury shares):

| | |
|--------------------|-------------------|
| December 31, 2024: | 47,911,185 shares |
| March 31, 2024: | 49,311,185 shares |
 - 2) Total number of treasury shares at the end of the period:

| | |
|--------------------|------------------|
| December 31, 2024: | 5,106,086 shares |
| March 31, 2024: | 5,105,798 shares |
 - 3) Average number of shares during the period:

| | |
|--------------------------------------|-------------------|
| Nine months ended December 31, 2024: | 43,894,126 shares |
| Nine months ended December 31, 2023: | 45,591,112 shares |

* Review of the Japanese-language originals of the attached quarterly consolidated financial statements by certified public accountants or an audit firm: None

* Explanation of the proper use of financial results forecast and other notes

(Cautionary note on forward-looking statements)

The financial forecasts and other forward-looking statements herein are based on information available to the Company as of the date of publication of this document and certain assumptions as of the date of publication of this document on uncertainties that may have an impact on future financial results and the Company does not in any way guarantee their achievement. Actual results may differ greatly from these forecasts due to a variety of factors. Please refer to “1. Overview of Operating Results, etc. (3) Explanation of Consolidated Financial Results Forecast and Other Forward-looking Information” on page 3 of the Attachments for preconditions underlying the financial forecasts and other matters.

(How to obtain supplementary explanatory materials on financial results)

The supplementary explanatory materials on financial results are posted on the Company’s website together with the consolidated financial results.

Table of Contents - Attachments

| | |
|--|----|
| 1. Overview of Operating Results, etc. | 2 |
| (1) Overview of Operating Results for the Period under Review | 2 |
| (2) Overview of Financial Position for the Period under Review | 3 |
| (3) Explanation of Consolidated Financial Results Forecast and Other Forward-looking Information | 3 |
| 2. Quarterly Consolidated Financial Statements and Principal Notes | 4 |
| (1) Quarterly Consolidated Balance Sheets | 4 |
| (2) Quarterly Consolidated Statements of Income and Comprehensive Income | 6 |
| (3) Notes to Quarterly Consolidated Financial Statements | 8 |
| (Segment information, etc.) | 8 |
| (Notes in case of significant changes in shareholders' equity) | 10 |
| (Notes on going concern assumption) | 10 |
| (Notes on statements of cash flows) | 10 |
| (Significant subsequent events) | 10 |
| 3. Other | 11 |
| (1) Sales Results | 11 |

1. Overview of Operating Results, etc.

(1) Overview of Operating Results for the Period under Review

In the nine months ended December 31, 2024, the pharmaceutical industry continued to experience harsh business conditions. The drug price revision was implemented in April 2024 with measures to support drug prices such as classifying more items as unprofitable products for repricing, in addition to the reform of the National Health Insurance (NHI) drug pricing system which focuses on resolving the issues of drug lag and drug loss as well as assessment and promotion of innovation. However, the overall drug price remains subject to cost-containment trends due to the measures, including the implementation of the mid-year revision of drug prices, which has been set for April 2025 following the previous revision. Although ICT demand continued and there were also signs of a recovery in willingness for capital investment in the information services, construction and facility maintenance, and merchandising industries, the current business climate, particularly personal consumption, is weak due to the weak yen and price hike, and the competitive environment remained fierce.

In these circumstances, the Company's financial results for the nine months ended December 31, 2024 were as stated below.

(Million yen)

| | Nine months ended December 31, 2023 | Nine months ended December 31, 2024 | Change (%) |
|--|--|--|------------|
| Net sales | 57,859 | 65,669 | 13.5 |
| Operating profit | 4,164 | 4,238 | 1.8 |
| Ordinary profit | 6,100 | 5,298 | (13.1) |
| Profit attributable to owners of parent | 8,337 | 8,840 | 6.0 |

• Net sales

Net sales of the Pharmaceutical Business were ¥56,572 million, an increase of 16.4% year on year. In addition to the sales of Beova[®] Tablets, an overactive bladder treatment, sales increased for four products (TAVNEOS[®] Capsules for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; KORSUVA[®] IV Injection Syringe, a treatment for pruritus in dialysis patients, TAVALISSE[®] Tablets, a treatment for chronic idiopathic thrombocytopenic purpura; and CAROGRA[®] Tablets, a treatment for ulcerative colitis), which were launched during the period of the medium-term management plan, "PEGASUS," and revenue from technical fees, etc. also increased. These factors contributed to the year-on-year increase in net sales.

In addition, Linzagolix (generic name), which was discovered by the Company and licensed out to Theramex (U.K.), was launched to the market in Germany in September 2024 under the product name Yselty[®] for the indication of uterine fibroids, followed by the launch and preparations for launch in other European countries. Furthermore, in November 2024, an additional indication of endometriosis for this drug was approved. The Company recorded revenue from technical fees based on an agreement with Theramex in relation to these developments.

Net sales of the Information Services Business were ¥5,987 million, a decrease of 2.4% year on year, net sales of the Construction and Facility Maintenance Business were ¥2,394 million, a decrease of 2.0% year on year, and net sales of the Merchandising Business were ¥715 million, an increase of 7.4% year on year.

• Profit

Regarding profit, the Company recorded higher operating profit due to an increase in net sales as well as improvement in the cost of sales ratio, despite an increase in selling, general and administrative expenses centering on R&D expenses. However, the Company's ordinary profit decreased because of a decrease in non-operating income, while profit attributable to owners of parent increased. The Company also recorded gain on sale of investment securities as extraordinary income. Additionally, in relation to the termination of the domestic co-promotion agreement with Ferring Pharmaceuticals Co., Ltd. for Minirin Melt[®] and Desmopressin formulations on March 31, 2025, the reversal of long-term prepaid expenses (impairment losses on marketing rights) was recorded as extraordinary losses.

- R&D

Linzagolix (generic name, development code: KLH-2109), which was discovered by the Company, achieved primary endpoints in two Phase III clinical trials in Japan for the indication of uterine fibroids, and the Company is preparing for an NDA. Additionally, the Company has also begun preparations for Phase III clinical trials in Japan for the additional indication of endometriosis. Preparations have also begun for additional Phase III clinical trials in Japan for a treatment for spinocerebellar degeneration Rovatirelin (generic name, development code: KPS-0373). In September 2024, the Company entered into an agreement with Rigel Pharmaceuticals, Inc. (U.S.) to acquire exclusive rights to develop and market the acute myeloid leukemia (AML) drug Olutasidenib (generic name) in Japan, South Korea, and Taiwan.

In the overseas development of Linzagolix, the Company granted exclusive rights to develop and market Linzagolix in South Korea to JW Pharmaceutical (South Korea) in June 2024. In September 2024, the Company notified Bio Genuine (China) of the termination of the licensing agreement granting it rights to develop and market the treatment in China and other countries.

In January 2025, the Company entered into a sub-licensing agreement with Tai Tien Pharmaceuticals Co., Ltd. (Taiwan, a consolidated subsidiary of Mitsubishi Tanabe Pharma Corporation) granting it rights to develop and market in Taiwan Fostamatinib (generic name, domestic brand name: TAVALISSE[®] Tablets), a treatment for chronic idiopathic thrombocytopenic purpura, which the Company in-licensed from Rigel Pharmaceuticals, Inc. In January 2025, JW Pharmaceutical (South Korea), the sublicensee of the drug in South Korea, has obtained marketing authorization for the same indication.

The development of KSP-0243 (development code), a treatment for ulcerative colitis originally discovered by the Company, was discontinued due to failure to meet primary endpoints in an early Phase II clinical trials.

(2) Overview of Financial Position for the Period under Review

- Assets

Total assets amounted to ¥248,930 million as of December 31, 2024, down ¥11,998 million from the previous fiscal year-end. Current assets were up ¥2,202 million, to ¥106,754 million, mainly due to an increase in notes and accounts receivable - trade, and contract assets despite a decrease in cash and deposits. Non-current assets were down ¥14,201 million, to ¥142,176 million, mainly due to a decrease in investment securities despite an increase in property, plant and equipment such as construction in progress.

- Liabilities

Total liabilities amounted to ¥37,612 million as of December 31, 2024, down ¥2,180 million from the previous fiscal year-end. Current liabilities were up ¥2,176 million, to ¥19,839 million, mainly due to an increase in accounts payable included in “Other” despite decreases in income taxes payable and contract liabilities. Non-current liabilities were down ¥4,357 million, to ¥17,772 million, mainly due to a decrease in deferred tax liabilities.

- Net assets

Total net assets amounted to ¥211,318 million as of December 31, 2024, down ¥9,817 million from the previous fiscal year-end, mainly due to a decrease in valuation difference on available-for-sale securities as well as the purchase and retirement of treasury shares despite an increase in retained earnings.

As a result, the shareholders' equity ratio was 84.4%, up from 84.3% at the previous fiscal year-end.

(3) Explanation of Consolidated Financial Results Forecast and Other Forward-looking Information

The consolidated financial results forecast for the fiscal year ending March 31, 2025 is unchanged from the consolidated financial results forecast announced on November 5, 2024.

2. Quarterly Consolidated Financial Statements and Principal Notes

(1) Quarterly Consolidated Balance Sheets

(Million yen)

| | As of March 31, 2024 | As of December 31, 2024 |
|--|----------------------|-------------------------|
| Assets | | |
| Current assets | | |
| Cash and deposits | 22,894 | 18,667 |
| Notes and accounts receivable - trade, and contract assets | 28,680 | 32,854 |
| Securities | 23,039 | 25,793 |
| Merchandise and finished goods | 14,310 | 13,997 |
| Work in process | 304 | 481 |
| Raw materials and supplies | 11,682 | 12,000 |
| Other | 3,640 | 2,960 |
| Total current assets | 104,551 | 106,754 |
| Non-current assets | | |
| Property, plant and equipment | | |
| Buildings and structures | 38,954 | 39,262 |
| Accumulated depreciation | (30,954) | (30,910) |
| Buildings and structures, net | 7,999 | 8,351 |
| Land | 13,594 | 13,067 |
| Construction in progress | 383 | 1,316 |
| Other | 16,855 | 17,232 |
| Accumulated depreciation | (13,972) | (14,000) |
| Other, net | 2,883 | 3,231 |
| Total property, plant and equipment | 24,861 | 25,967 |
| Intangible assets | 1,992 | 1,859 |
| Investments and other assets | | |
| Investment securities | 106,361 | 92,075 |
| Retirement benefit asset | 7,311 | 7,856 |
| Deferred tax assets | 608 | 408 |
| Other | 15,260 | 14,028 |
| Allowance for doubtful accounts | (18) | (18) |
| Total investments and other assets | 129,523 | 114,349 |
| Total non-current assets | 156,377 | 142,176 |
| Total assets | 260,929 | 248,930 |

(Million yen)

| | As of March 31, 2024 | As of December 31, 2024 |
|--|----------------------|-------------------------|
| Liabilities | | |
| Current liabilities | | |
| Notes and accounts payable - trade | 4,893 | 5,115 |
| Short-term borrowings | 1,340 | 1,280 |
| Income taxes payable | 2,380 | 1,237 |
| Provision for bonuses | 1,847 | 874 |
| Other provisions | 153 | 157 |
| Contract liabilities | 1,486 | 1,063 |
| Other | 5,562 | 10,111 |
| Total current liabilities | 17,663 | 19,839 |
| Non-current liabilities | | |
| Deferred tax liabilities | 21,188 | 16,873 |
| Provision for retirement benefits for directors (and other officers) | 209 | 198 |
| Asset retirement obligations | 143 | 143 |
| Other | 588 | 557 |
| Total non-current liabilities | 22,129 | 17,772 |
| Total liabilities | 39,793 | 37,612 |
| Net assets | | |
| Shareholders' equity | | |
| Share capital | 24,356 | 24,356 |
| Capital surplus | 24,226 | 24,226 |
| Retained earnings | 127,310 | 128,367 |
| Treasury shares | (13,209) | (14,520) |
| Total shareholders' equity | 162,683 | 162,429 |
| Accumulated other comprehensive income | | |
| Valuation difference on available-for-sale securities | 52,782 | 43,476 |
| Remeasurements of defined benefit plans | 4,562 | 4,296 |
| Total accumulated other comprehensive income | 57,344 | 47,773 |
| Non-controlling interests | 1,107 | 1,115 |
| Total net assets | 221,136 | 211,318 |
| Total liabilities and net assets | 260,929 | 248,930 |

(2) Quarterly Consolidated Statements of Income and Comprehensive Income
Quarterly Consolidated Statements of Income
Nine Months Ended December 31

(Million yen)

| | For the nine months ended December 31, 2023 | For the nine months ended December 31, 2024 |
|--|--|--|
| Net sales | 57,859 | 65,669 |
| Cost of sales | 29,294 | 32,551 |
| Gross profit | 28,565 | 33,118 |
| Selling, general and administrative expenses | 24,400 | 28,880 |
| Operating profit | 4,164 | 4,238 |
| Non-operating income | | |
| Interest income | 39 | 33 |
| Dividend income | 1,225 | 1,295 |
| Gain on sale of securities | 540 | – |
| Gain on valuation of securities | 189 | – |
| Other | 72 | 63 |
| Total non-operating income | 2,067 | 1,392 |
| Non-operating expenses | | |
| Interest expenses | 13 | 15 |
| Loss on valuation of securities | – | 77 |
| Foreign exchange losses | 64 | 187 |
| Other | 54 | 50 |
| Total non-operating expenses | 131 | 331 |
| Ordinary profit | 6,100 | 5,298 |
| Extraordinary income | | |
| Gain on sale of non-current assets | 12 | 0 |
| Gain on sale of investment securities | 5,020 | 9,329 |
| Total extraordinary income | 5,032 | 9,329 |
| Extraordinary losses | | |
| Loss on sale of non-current assets | – | 0 |
| Loss on disposal of non-current assets | 31 | 158 |
| Impairment losses | – | 2,895 |
| Loss on valuation of investment securities | 1 | – |
| Total extraordinary losses | 32 | 3,054 |
| Profit before income taxes | 11,100 | 11,574 |
| Income taxes - current | 1,727 | 2,634 |
| Income taxes - deferred | 920 | 84 |
| Total income taxes | 2,648 | 2,719 |
| Profit | 8,452 | 8,854 |
| Profit attributable to non-controlling interests | 115 | 14 |
| Profit attributable to owners of parent | 8,337 | 8,840 |

Quarterly Consolidated Statements of Comprehensive Income

Nine Months Ended December 31

(Million yen)

| | For the nine months ended December 31, 2023 | For the nine months ended December 31, 2024 |
|--|--|--|
| Profit | 8,452 | 8,854 |
| Other comprehensive income | | |
| Valuation difference on available-for-sale securities | 3,455 | (9,306) |
| Remeasurements of defined benefit plans, net of tax | (210) | (271) |
| Total other comprehensive income | 3,244 | (9,577) |
| Comprehensive income | 11,697 | (723) |
| Comprehensive income attributable to | | |
| Comprehensive income attributable to owners of parent | 11,570 | (730) |
| Comprehensive income attributable to non-controlling interests | 126 | 7 |

(3) Notes to Quarterly Consolidated Financial Statements

(Segment information, etc.)

I. For the nine months ended December 31, 2023 (from April 1, 2023 to December 31, 2023)

1. Information on net sales and profit (loss), and information on the disaggregation of revenue by reportable segment

(Million yen)

| | Reportable segment | | | | Total |
|--|--------------------|----------------------|---------------------------------------|---------------|--------|
| | Pharmaceutical | Information Services | Construction and Facility Maintenance | Merchandising | |
| Net sales | | | | | |
| Pharmaceutical Business | | | | | |
| Pharmaceuticals sales | 41,414 | – | – | – | 41,414 |
| Therapeutic and care foods sales | 2,776 | – | – | – | 2,776 |
| Technical fees | 649 | – | – | – | 649 |
| Other | 3,775 | – | – | – | 3,775 |
| Information Services Business | – | 7,590 | – | – | 7,590 |
| Construction and Facility Maintenance Business | – | – | 3,654 | – | 3,654 |
| Merchandising Business | – | – | – | 787 | 787 |
| Revenue arising from contracts with customers | 48,616 | 7,590 | 3,654 | 787 | 60,648 |
| Sales to third parties | 48,616 | 6,132 | 2,443 | 666 | 57,859 |
| Inter-segment sales or transfers | – | 1,457 | 1,210 | 121 | 2,789 |
| Total | 48,616 | 7,590 | 3,654 | 787 | 60,648 |
| Segment profit | 2,849 | 968 | 214 | 81 | 4,113 |

2. Total amount of profit (loss) of reportable segments, difference from the amount stated in the quarterly consolidated statements of income, and main components of such difference

(Million yen)

| Profit | Amount |
|---|--------|
| Total for reportable segments | 4,113 |
| Elimination of inter-segment transactions | 65 |
| Adjustment of non-current assets | (17) |
| Other adjustments | 2 |
| Operating profit in the quarterly consolidated statements of income | 4,164 |

II. For the nine months ended December 31, 2024 (from April 1, 2024 to December 31, 2024)

1. Information on net sales and profit (loss), and information on the disaggregation of revenue by reportable segment

(Million yen)

| | Reportable segment | | | | Total |
|--|--------------------|----------------------|---------------------------------------|---------------|--------|
| | Pharmaceutical | Information Services | Construction and Facility Maintenance | Merchandising | |
| Net sales | | | | | |
| Pharmaceutical Business | | | | | |
| Pharmaceuticals sales | 48,252 | – | – | – | 48,252 |
| Therapeutic and care foods sales | 2,787 | – | – | – | 2,787 |
| Technical fees | 1,876 | – | – | – | 1,876 |
| Other | 3,655 | – | – | – | 3,655 |
| Information Services Business | – | 7,792 | – | – | 7,792 |
| Construction and Facility Maintenance Business | – | – | 4,294 | – | 4,294 |
| Merchandising Business | – | – | – | 865 | 865 |
| Revenue arising from contracts with customers | 56,572 | 7,792 | 4,294 | 865 | 69,524 |
| Sales to third parties | 56,572 | 5,987 | 2,394 | 715 | 65,669 |
| Inter-segment sales or transfers | – | 1,805 | 1,899 | 150 | 3,854 |
| Total | 56,572 | 7,792 | 4,294 | 865 | 69,524 |
| Segment profit | 3,512 | 307 | 339 | 98 | 4,257 |

2. Total amount of profit (loss) of reportable segments, difference from the amount stated in the quarterly consolidated statements of income, and main components of such difference

(Million yen)

| Profit | Amount |
|---|--------|
| Total for reportable segments | 4,257 |
| Elimination of inter-segment transactions | 60 |
| Adjustment of non-current assets | (69) |
| Other adjustments | (10) |
| Operating profit in the quarterly consolidated statements of income | 4,238 |

3. Information on impairment losses on non-current assets and goodwill by reportable segment

In the Pharmaceutical Business segment, an impairment loss was recorded in connection with the termination of the agreement with Ferring Pharmaceuticals Co., Ltd. regarding the licensing of domestic sales rights for Minirin Melt® and Desmopressin formulations.

The amount of impairment losses recorded was ¥2,768 million.

4. Disclosure of changes in reportable segments, etc.

(Changes in reportable segments)

Effective from the six months ended September 30, 2024, the reportable segment “Construction Business” has been renamed “Construction and Facility Maintenance Business” to more clearly reflect the nature of the business. This change is only in the name and has no impact on segment information.

The segment information for the nine months ended December 31, 2023 is also presented under the new name.

(Notes in case of significant changes in shareholders' equity)

In accordance with a resolution at the Board of Directors' meeting held on November 5, 2024, the Company repurchased 1,400,000 shares of treasury shares for ¥5,292 million. In addition, the Company retired 1,400,000 shares of treasury shares for ¥3,981 million on November 29, 2024. Consequently, for the nine months ended December 31, 2024, retained earnings decreased by ¥3,981 million and treasury shares increased by ¥1,311 million, resulting in ¥128,367 million in retained earnings and ¥14,520 million in treasury shares as of December 31, 2024.

(Notes on going concern assumption)

Not applicable.

(Notes on statements of cash flows)

Quarterly consolidated statements of cash flows for the nine months ended December 31, 2024 have not been prepared. Depreciation (including amortization for intangible assets) for the nine months ended December 31, 2023 and 2024 is as follows.

| | For the nine months ended December 31, 2023 | For the nine months ended December 31, 2024 |
|--------------|--|--|
| Depreciation | 3,116 million yen | 3,455 million yen |

(Significant subsequent events)

(Execution of Significant Contract)

The Company entered into a sub-licensing agreement with Tai Tien Pharmaceuticals Co., Ltd. (Taiwan, hereinafter "Tai Tien Pharmaceuticals"), a consolidated subsidiary of Mitsubishi Tanabe Pharma Corporation, to license the development and marketing rights in Taiwan for Fostamatinib (generic name), a treatment for chronic idiopathic thrombocytopenic purpura discovered by Rigel Pharmaceuticals, Inc. (U.S.). The outline is as follows.

(1) Name of the counterparty of the contract

Tai Tien Pharmaceuticals Co., Ltd. (Taiwan)

(2) Date of the contract

January 7, 2025

(3) Details of the contract

To grant "Tai Tien Pharmaceuticals" the development and marketing rights for Fostamatinib in Taiwan

(4) Significant effect of the execution of the contract on the Company's operations

By executing this contract, the Company will receive an upfront payment and milestone payments based on the progress of commercialization in Taiwan from Tai Tien Pharmaceuticals and will supply the formulation to Tai Tien Pharmaceuticals.

3. Other

(1) Sales Results

Sales results by segment for the nine months ended December 31, 2024 are as follows.

| Segment classification | Nine months ended December 31, 2023 | | Nine months ended December 31, 2024 | | Change | |
|--|--|--------------------|--|--------------------|-------------------------|---------------|
| | Amount (Million yen) | Composition (%) | Amount (Million yen) | Composition (%) | Amount (Million yen) | Change (%) |
| Pharmaceutical Business | 48,616 | 84.0 | 56,572 | 86.1 | 7,955 | 16.4 |
| Urology | 16,171 | 27.9 | 17,807 | 27.1 | 1,635 | 10.1 |
| Renal diseases and dialysis | 9,901 | 17.1 | 12,060 | 18.4 | 2,159 | 21.8 |
| Orphan drugs | 4,405 | 7.6 | 8,469 | 12.9 | 4,063 | 92.2 |
| Metabolism and endocrinology | 4,489 | 7.8 | 3,646 | 5.6 | (843) | (18.8) |
| Obstetrics and gynecology | 554 | 1.0 | 496 | 0.8 | (58) | (10.5) |
| Ophthalmology | 279 | 0.5 | 206 | 0.3 | (73) | (26.2) |
| Other drugs | 5,613 | 9.7 | 5,567 | 8.5 | (45) | (0.8) |
| Therapeutic and care foods | 2,776 | 4.8 | 2,787 | 4.2 | 10 | 0.4 |
| Technical fees | 649 | 1.1 | 1,876 | 2.9 | 1,226 | 188.8 |
| Other | 3,775 | 6.5 | 3,655 | 5.6 | (119) | (3.2) |
| Information Services Business | 6,132 | 10.6 | 5,987 | 9.1 | (145) | (2.4) |
| Construction and Facility Maintenance Business | 2,443 | 4.2 | 2,394 | 3.6 | (48) | (2.0) |
| Merchandising Business | 666 | 1.2 | 715 | 1.1 | 49 | 7.4 |
| Total | 57,859 | 100.0 | 65,669 | 100.0 | 7,810 | 13.5 |
| [Exports] | [3,470] | [6.0] | [4,805] | [7.3] | [1,335] | [38.5] |

(Note) Inter-segment transactions are eliminated.